Sofosbuvir / velpatasvir (Epclusa 400 mg/100 mg Film Kaplı Tablet) and Tenofovir disoproxil fumarate: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Sofosbuvir/velpatasvir increases tenofovir exposure from TDF.
Clinical significance and safety
Epclusa 400 mg/100 mg film-coated tablet can increase tenofovir exposure when used with TDF. The label recommends monitoring for TDF-associated adverse reactions; baseline renal function, HIV boosters and other nephrotoxic medicines are relevant to review. This information is specific to tenofovir disoproxil fumarate, not an automatic management rule for tenofovir alafenamide.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.